AbbVie Positive Topline Results from Phase 2 Lung Cancer Trial

 

• LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints
• Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression
• Data from the study will be presented at a future medical meeting and we will discuss with global health authorities the potential to support an accelerated approval

https://www.prnewswire.com/news-releases/abbvie-announces-positive-topline-results-from-phase-2-luminosity-trial-evaluating-telisotuzumab-vedotin-teliso-v-for-patients-with-previously-treated-non-small-cell-lung-cancer-nsclc-302000674.html